Results 121 to 130 of about 529 (145)

Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms. [PDF]

Front Immunol
He L, Sun Y, Ma B, Lang G, Wen J, Blumenschein GR, Ma H.   +6 more
europepmc   +1 more source

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). [PDF]

J Immunother Cancer
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A.   +19 more
europepmc   +1 more source

Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. [PDF]

Clin Cancer Res
Negrao MV, Paula AG, Molkentine D, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Diao L, Altan M, Blumenschein GR, Skoulidis F, Wang J, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen JG, Heymach JV.   +21 more
europepmc   +1 more source

Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma? [PDF]

Front Immunol
Smith H, Arbe-Barnes E, Shah EA, Sivakumar S.   +3 more
europepmc   +1 more source

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. [PDF]

J Immunother Cancer
Zhou N, Leung CH, William WN, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T.   +36 more
europepmc   +1 more source

A gut microbial signature for combination immune checkpoint blockade across cancer types. [PDF]

Nat Med
Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak BW, Markman B, Kee D, Carlino MS, Underhill C, Frentzas S, Michael M, Gao B, Palmer J, Cebon J, Behren A, Adams DJ, Lawley TD.   +17 more
europepmc   +1 more source

The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.

Int Arch Allergy Immunol
Sehgal ANA, Tauber PA, Stieger RB, Kratzer B, Pickl WF.   +4 more
europepmc   +1 more source

Eating epilepsy. Heterogeneity of ictal semiology: the role of video-EEG monitoring.

, 2000
D' Aulos F, Nocerino C, Loreto V, Striano S., STRIANO, PASQUALE, Boccella P   +5 more
core  

Some of the next articles are maybe not open access.

Related searches:

Three Virtuosos of the Aulos from Boeotia: Antigenidas, Ismenias, and Timotheos Die opéras-comiques egidio dunis auf deutschen bühnen

Archiv Fur Musikwissenschaft, 2023
exaly  

Eco-friendly dual-band AULOS® passive radar for air and maritime surveillance applications

2018
Fabiola Colone, Tatiana Martelli, Roberta Cardinali   +2 more
exaly